Synthetic immunology: modulating the human immune system.
暂无分享,去创建一个
[1] C. Polman,et al. Natalizumab: bench to bedside and beyond. , 2013, JAMA neurology.
[2] M. Vogel,et al. Accelerated dissociation of IgE-FcεRI complexes by disruptive inhibitors actively desensitizes allergic effector cells. , 2014, The Journal of allergy and clinical immunology.
[3] Martin Fussenegger,et al. Smart medication through combination of synthetic biology and cell microencapsulation. , 2012, Metabolic engineering.
[4] D. Furst. Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis. , 2004, Clinical therapeutics.
[5] P. Dilger,et al. Engineering of the gut commensal bacterium Bacteroides ovatus to produce and secrete biologically active murine interleukin‐2 in response to xylan , 2005, Journal of applied microbiology.
[6] M. Merino,et al. T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.
[7] J. Chatel,et al. Engineering lactococci and lactobacilli for human health. , 2013, Current opinion in microbiology.
[8] Michel Sadelain,et al. Hematopoietic stem cell engineering at a crossroads. , 2012, Blood.
[9] Raphael Sandaltzopoulos,et al. Chimeric Antigen Receptor T Cells with Dissociated Signaling Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In Vivo , 2013, Cancer Immunology Research.
[10] Jianren Gu,et al. An EpCAM/CD3 bispecific antibody efficiently eliminates hepatocellular carcinoma cells with limited galectin-1 expression , 2014, Cancer Immunology, Immunotherapy.
[11] L. Naldini,et al. CD4+ T Cells from IPEX Patients Convert into Functional and Stable Regulatory T Cells by FOXP3 Gene Transfer , 2013, Science Translational Medicine.
[12] Bernd Hauck,et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.
[13] E. Remaut,et al. Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis. , 2006, Arthritis and rheumatism.
[14] M. Clark,et al. Antibody humanization: a case of the 'Emperor's new clothes'? , 2000, Immunology today.
[15] Thomas Singer,et al. The safety and side effects of monoclonal antibodies , 2010, Nature Reviews Drug Discovery.
[16] Christian Bailly,et al. Strategies and challenges for the next generation of therapeutic antibodies , 2010, Nature Reviews Immunology.
[17] M. Kay. State-of-the-art gene-based therapies: the road ahead , 2011, Nature Reviews Genetics.
[18] M. Pirmohamed,et al. Challenges and approaches for the development of safer immunomodulatory biologics , 2013, Nature Reviews Drug Discovery.
[19] David C. Smith,et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.
[20] David A Spiegel,et al. Grand challenge commentary: Synthetic immunology to engineer human immunity. , 2010, Nature chemical biology.
[21] N. Restifo,et al. Reassessing target antigens for adoptive T cell therapy , 2013, Nature Biotechnology.
[22] Vibha Jawa,et al. T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation. , 2013, Clinical immunology.
[23] Christina D Smolke,et al. Genetic control of mammalian T-cell proliferation with synthetic RNA regulatory systems , 2010, Proceedings of the National Academy of Sciences.
[24] S. Rosenberg,et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. , 2009, Blood.
[25] Jin Ma,et al. Therapeutic Inflammatory Monocyte Modulation Using Immune-Modifying Microparticles , 2014, Science Translational Medicine.
[26] C. Heeschen,et al. EpCAM/CD3-Bispecific T-cell Engaging Antibody MT110 Eliminates Primary Human Pancreatic Cancer Stem Cells , 2011, Clinical Cancer Research.
[27] H. Simon,et al. Living and dying for inflammation: neutrophils, eosinophils, basophils. , 2013, Trends in immunology.
[28] J. Bartlett,et al. CCR5 as a Natural and Modulated Target for Inhibition of HIV , 2013, Viruses.
[29] Martin Fussenegger,et al. Self-sufficient control of urate homeostasis in mice by a synthetic circuit , 2010, Nature Biotechnology.
[30] M. Zurini,et al. Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates. , 2012, Biotechnology journal.
[31] P. Kufer,et al. Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells. , 2009, Leukemia research.
[32] L. Naldini. Ex vivo gene transfer and correction for cell-based therapies , 2011, Nature Reviews Genetics.
[33] H. Gendelman,et al. Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. , 2006, Blood.
[34] N. Popitsch,et al. CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients , 2013, Clinical Cancer Research.
[35] J. Hess,et al. Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients , 2010, British journal of clinical pharmacology.
[36] Karolina Palucka,et al. Cancer immunotherapy via dendritic cells , 2012, Nature Reviews Cancer.
[37] P. Moore,et al. Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma. , 2011, Blood.
[38] J. P. McCoy,et al. Reduction of GVHD and enhanced antitumor effects after adoptive infusion of alloreactive Ly49-mismatched NK cells from MHC-matched donors. , 2007, Blood.
[39] A. Petrov,et al. Omalizumab and hypersensitivity reactions , 2013, Current opinion in allergy and clinical immunology.
[40] Jeffrey A Hubbell,et al. Engineering Approaches to Immunotherapy , 2012, Science Translational Medicine.
[41] Michel Sadelain,et al. PD-1– and CTLA-4–Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses , 2013, Science Translational Medicine.
[42] Vanessa Taupin,et al. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo , 2010, Nature Biotechnology.
[43] Jérôme Larghero,et al. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia , 2010, Nature.
[44] P. Linsley,et al. The clinical utility of inhibiting CD28‐mediated costimulation , 2009, Immunological reviews.
[45] A. Bagg,et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.
[46] Steven A. Rosenberg,et al. Adoptive immunotherapy for cancer: harnessing the T cell response , 2012, Nature Reviews Immunology.
[47] Michaela Gebauer,et al. Anticalins small engineered binding proteins based on the lipocalin scaffold. , 2012, Methods in enzymology.
[48] Christopher G. Parker,et al. Antibody-recruiting molecules: an emerging paradigm for engaging immune function in treating human disease. , 2012, ACS chemical biology.
[49] F. Lienert,et al. Synthetic biology in mammalian cells: next generation research tools and therapeutics , 2014, Nature Reviews Molecular Cell Biology.
[50] Soong Ho Um,et al. Therapeutic cell engineering using surface-conjugated synthetic nanoparticles , 2010, Nature Medicine.
[51] Richard A Fekete,et al. Toward a live microbial microbicide for HIV: commensal bacteria secreting an HIV fusion inhibitor peptide. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[52] S. Chimenti,et al. Adalimumab in the Treatment of Immune-Mediated Diseases , 2014, International journal of immunopathology and pharmacology.
[53] A. Melcher,et al. Cell carriers for oncolytic viruses: Fed Ex for cancer therapy. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.
[54] M. Sadelain,et al. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.
[55] S. Elledge,et al. The DNA damage response: making it safe to play with knives. , 2010, Molecular cell.
[56] D. Chelius,et al. Structural and functional characterization of the trifunctional antibody catumaxomab , 2010, mAbs.
[57] C. Barbas,et al. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. , 2013, Trends in biotechnology.
[58] J. Galipeau,et al. Mechanisms of immune modulation by mesenchymal stromal cells and clinical translation. , 2013, Current molecular medicine.
[59] W. Murphy,et al. Advantages and clinical applications of natural killer cells in cancer immunotherapy , 2013, Cancer Immunology, Immunotherapy.
[60] J. Kocik,et al. Synthetic immunostimulatory oligonucleotides in experimental and clinical practice , 2012, Pharmacological reports : PR.
[61] J. Teillaud. From whole monoclonal antibodies to single domain antibodies: think small. , 2012, Methods in molecular biology.
[62] Pamela A Silver,et al. Enhancement of Cell Type Specificity by Quantitative Modulation of a Chimeric Ligand* , 2008, Journal of Biological Chemistry.
[63] M. Lebwohl,et al. The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. , 2005, Seminars in arthritis and rheumatism.
[64] M. Friedrich,et al. Regression of Human Prostate Cancer Xenografts in Mice by AMG 212/BAY2010112, a Novel PSMA/CD3-Bispecific BiTE Antibody Cross-Reactive with Non-Human Primate Antigens , 2012, Molecular Cancer Therapeutics.
[65] Benjamin Rhau,et al. Synthetic control of mammalian-cell motility by engineering chemotaxis to an orthogonal bioinert chemical signal , 2014, Proceedings of the National Academy of Sciences.
[66] M. E. Bonk,et al. Rilonacept (arcalyst), an interleukin-1 trap for the treatment of cryopyrin-associated periodic syndromes. , 2009, P & T : a peer-reviewed journal for formulary management.
[67] P. Kantoff,et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.
[68] L. Cosler,et al. Pegfilgrastim: a review of the pharmacoeconomics for chemotherapy-induced neutropenia , 2012, Expert review of pharmacoeconomics & outcomes research.
[69] S. Magez,et al. Novel therapy based on camelid nanobodies. , 2013, Therapeutic delivery.
[70] David L Porter,et al. Chimeric antigen receptor therapy for cancer. , 2014, Annual review of medicine.
[71] Wei-Ting Hwang,et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. , 2014, The New England journal of medicine.
[72] Jos W. M. van der Meer,et al. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases , 2012, Nature Reviews Drug Discovery.
[73] J. Orange,et al. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases , 2008, Nature Biotechnology.
[74] J. Mitchell,et al. Pharmacology and therapeutic potential of interferons. , 2012, Pharmacology & therapeutics.
[75] M. Suarez‐Almazor,et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews , 2009, The Cochrane database of systematic reviews.
[76] Aoshuang Chen,et al. Arming tumor-reactive T cells with costimulator B7-1 enhances therapeutic efficacy of the T cells. , 2006, Cancer research.
[77] W. Stemmer,et al. Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains , 2005, Nature biotechnology.
[78] H. Simon,et al. Protein overexpression following lentiviral infection of primary mature neutrophils is due to pseudotransduction. , 2011, Journal of immunological methods.
[79] Wendell A. Lim,et al. Bacterial Virulence Proteins as Tools to Rewire Kinase Pathways in Yeast and Immune Cells , 2012, Nature.
[80] Luca Biasco,et al. Lentiviral Hematopoietic Stem Cell Gene Therapy in Patients with Wiskott-Aldrich Syndrome , 2013, Science.
[81] S. Rosenberg,et al. Bcl-2 overexpression enhances tumor-specific T-cell survival. , 2005, Cancer research.
[82] Martin Fussenegger,et al. A synthetic multifunctional mammalian pH sensor and CO2 transgene-control device. , 2014, Molecular cell.
[83] T. Wurch,et al. Novel protein scaffolds as emerging therapeutic proteins: from discovery to clinical proof-of-concept. , 2012, Trends in biotechnology.
[84] Michel Sadelain,et al. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells , 2012, Nature Biotechnology.
[85] R. Hansen,et al. Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug Effectiveness Review Project , 2009, Biologics : targets & therapy.
[86] A. Vatrella,et al. The potential of biologics for the treatment of asthma , 2012, Nature Reviews Drug Discovery.
[87] P. Kufer,et al. Blinatumomab: a historical perspective. , 2012, Pharmacology & therapeutics.
[88] P. Robbins,et al. Regulation of immune responses by extracellular vesicles , 2014, Nature Reviews Immunology.
[89] M. Kalos,et al. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. , 2013, Immunity.
[90] P. Baeuerle,et al. Targeting T cells to tumor cells using bispecific antibodies. , 2013, Current opinion in chemical biology.
[91] S. Rosenberg,et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.
[92] M. McDermott. Rilonacept in the treatment of chronic inflammatory disorders. , 2009, Drugs of today.
[93] NK cell-based immunotherapy for malignant diseases , 2013, Cellular and Molecular Immunology.
[94] M. Little,et al. A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells , 2014, mAbs.
[95] M. Coffey,et al. Internalization of Oncolytic Reovirus by Human Dendritic Cell Carriers Protects the Virus from Neutralization , 2011, Clinical Cancer Research.
[96] T. Daniels,et al. Antibody–cytokine fusion proteins: applications in cancer therapy , 2008, Expert opinion on biological therapy.
[97] C. Cordon-Cardo,et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[98] S. Muyldermans,et al. Nanobody-based products as research and diagnostic tools. , 2014, Trends in biotechnology.
[99] M. Little,et al. T and NK cells of B cell NHL patients exert cytotoxicity against lymphoma cells following binding of bispecific tetravalent antibody CD19 × CD3 or CD19 × CD16 , 2012, Cancer Immunology, Immunotherapy.
[100] Atique U. Ahmed,et al. Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells , 2005, Nature Medicine.
[101] J. Jurcic. What Happened to Anti-CD33 Therapy for Acute Myeloid Leukemia? , 2012, Current Hematologic Malignancy Reports.
[102] David L. Porter,et al. T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia , 2011, Science Translational Medicine.
[103] A. Henn,et al. Preclinical Characterization of AMG 330, a CD3/CD33-Bispecific T-Cell–Engaging Antibody with Potential for Treatment of Acute Myelogenous Leukemia , 2014, Molecular Cancer Therapeutics.
[104] S. Welsh,et al. The clinical use of granulocyte-colony stimulating factor. , 2014, British journal of hospital medicine.
[105] M. Vogel,et al. Accelerated Disassembly of IgE:Receptor Complexes by a Disruptive Macromolecular Inhibitor , 2012, Nature.
[106] R. Kontermann. Antibody-cytokine fusion proteins. , 2012, Archives of biochemistry and biophysics.
[107] Lei Dong,et al. Harnessing the power of macrophages/monocytes for enhanced bone tissue engineering. , 2013, Trends in biotechnology.
[108] R. Maciuca,et al. Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production , 2014, Science Translational Medicine.
[109] C. Horak,et al. Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.
[110] M. Sadelain,et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. , 2012, Blood.
[111] F. Marincola,et al. IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. , 2011, The Journal of clinical investigation.
[112] Darrell J Irvine,et al. Enhancing Cell therapies from the Outside In: Cell Surface Engineering Using Synthetic Nanomaterials. , 2011, Nano today.
[113] Martin Fussenegger,et al. A closed-loop synthetic gene circuit for the treatment of diet-induced obesity in mice , 2013, Nature Communications.
[114] Darrell J Irvine,et al. Engineering synthetic vaccines using cues from natural immunity. , 2013, Nature materials.
[115] Martin Fussenegger,et al. A designer cell-based histamine-specific human allergy profiler , 2014, Nature Communications.
[116] J. Wolchok,et al. Annals of the New York Academy of Sciences Development of Ipilimumab: a Novel Immunotherapeutic Approach for the Treatment of Advanced Melanoma , 2022 .
[117] F. Stivala,et al. Understanding rituximab function and resistance: implications for tailored therapy. , 2011, Frontiers in bioscience.